SPECTRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its Pinnacle Study of poziotinib for lung cancer treatment, impacting investors who acquired shares between March 17, 2022, and September 22, 2022 [2][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased Spectrum securities during the specified class period [2]. - Investors have until September 24, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations Against the Company - The complaint alleges that Spectrum's public statements regarding the Pinnacle Study were materially misleading and did not accurately reflect the study's outcomes [3]. - The company is accused of portraying the results of the study in a more positive light than warranted, which misled investors [3]. Group 3: Investor Support - Investors who suffered losses and are interested in learning more about their rights or the claims are encouraged to contact the law firm for assistance [4]. - The law firm, Bragar Eagel & Squire, P.C., offers no-cost consultations to affected investors [4]. Group 4: Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [5]. - The firm operates in multiple states, including New York, California, and South Carolina, and has a strong track record in securities and derivative litigation [5].